Citadel Advisors’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-34,400
| Closed | -$125K | – | 15344 |
|
|
2021
Q3 | $125K | Sell |
34,400
-21,000
| -38% | -$84.9K | ﹤0.01% | 12603 |
|
|
2021
Q2 | $242K | Buy |
55,400
+5,200
| +10% | +$21.2K | ﹤0.01% | 11773 |
|
|
2021
Q1 | $206K | Sell |
50,200
-6,100
| -11% | -$26.4K | ﹤0.01% | 11640 |
|
|
2020
Q4 | $225K | Sell |
56,300
-4,800
| -8% | -$15.5K | ﹤0.01% | 9563 |
|
|
2020
Q3 | $165K | Buy |
61,100
+22,500
| +58% | +$62.3K | ﹤0.01% | 8947 |
|
|
2020
Q2 | $106K | Sell |
38,600
-14,100
| -27% | -$39.3K | ﹤0.01% | 8963 |
|
|
2020
Q1 | $124K | Sell |
52,700
-36,200
| -41% | -$123K | ﹤0.01% | 8465 |
|
|
2019
Q4 | $418K | Sell |
88,900
-14,800
| -14% | -$60.6K | ﹤0.01% | 7100 |
|
|
2019
Q3 | $347K | Buy |
103,700
+8,100
| +8% | +$26.7K | ﹤0.01% | 7350 |
|
|
2019
Q2 | $315K | Sell |
95,600
-49,700
| -34% | -$144K | ﹤0.01% | 7519 |
|
|
2019
Q1 | $440K | Buy |
145,300
+11,300
| +8% | +$36.6K | ﹤0.01% | 7008 |
|
|
2018
Q4 | $364K | Buy |
134,000
+33,800
| +34% | +$111K | ﹤0.01% | 6930 |
|
|
2018
Q3 | $337K | Buy |
100,200
+70,300
| +235% | +$217K | ﹤0.01% | 7380 |
|
|
2018
Q2 | $77K | Buy |
+29,900
| New | +$74.4K | ﹤0.01% | 8337 |
|
|
2018
Q1 | – | Sell |
-14,000
| Closed | -$28K | – | 8985 |
|
|
2017
Q4 | $28K | Sell |
14,000
-6,500
| -32% | -$14.1K | ﹤0.01% | 7777 |
|
|
2017
Q3 | $66K | Buy |
+20,500
| New | +$63.3K | ﹤0.01% | 7132 |
|
|
2016
Q3 | – | Sell |
-14,500
| Closed | -$15K | – | 7960 |
|
|
2016
Q2 | $15K | Buy |
+14,500
| New | +$14K | ﹤0.01% | 6690 |
|
|
2016
Q1 | – | Sell |
-7,200
| Closed | -$9K | – | 8374 |
|
|
2015
Q4 | $9K | Sell |
7,200
-900
| -11% | -$1.25K | ﹤0.01% | 8316 |
|
|
2015
Q3 | $14K | Sell |
8,100
-2,200
| -21% | -$4.31K | ﹤0.01% | 8362 |
|
|
2015
Q2 | $21K | Buy |
10,300
+2,100
| +26% | +$5.09K | ﹤0.01% | 8132 |
|
|
2015
Q1 | $22K | Buy |
8,200
+6,000
| +273% | +$15.2K | ﹤0.01% | 7854 |
|
|
2014
Q4 | $6K | Sell |
2,200
-5,900
| -73% | -$13.3K | ﹤0.01% | 8251 |
|
|
2014
Q3 | $15K | Buy |
8,100
+6,400
| +376% | +$14K | ﹤0.01% | 7629 |
|
|
2014
Q2 | $5K | Sell |
1,700
-5,600
| -77% | -$16.9K | ﹤0.01% | 7734 |
|
|
2014
Q1 | $26K | Buy |
7,300
+3,800
| +109% | +$16.9K | ﹤0.01% | 7170 |
|
|
2013
Q4 | $16K | Sell |
3,500
-8,900
| -72% | -$36.3K | ﹤0.01% | 6578 |
|
|
2013
Q3 | $50K | Sell |
12,400
-13,600
| -52% | -$59.4K | ﹤0.01% | 5793 |
|
|
2013
Q2 | $108K | Buy |
+26,000
| New | +$100K | ﹤0.01% | 5169 |
|
Other funds holding ATRS
Citadel Advisors's ATRS Position: Q2 2022 in Review
Citadel Advisors sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 448,691 shares — an estimated $1.84M sold.
Citadel Advisors first reported a position in ATRS in Q2 2013 and held it in 34 quarters. The position peaked at $1.84M in Q1 2022. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Citadel Advisors reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Citadel Advisors sold 448,691 Antares Pharma, Inc. shares in Q2 2022, an estimated $1.84M.
- Citadel Advisors first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 34 quarters.
- Citadel Advisors's Antares Pharma, Inc. position peaked at $1.84M in Q1 2022.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.